Anthony G. Quinn, Director at Aeglea BioTherapeutics, Inc. (AGLE), bought 17,121 shares at $4.53 ($83K) on 2017-12-01, disclosed to the SEC on 2017-12-05.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.53 | 4,100 | $19K | 22.3% |
| 2 | $4.98 | 7,956 | $40K | 47.6% |
| 3 | $4.93 | 5,065 | $25K | 30.0% |
| Total | $4.86 avg | 17,121 | $83K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |